Abstract
The Comparison of Fulvestrant 250 mg and 500 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy [CONFIRM] trial compared treatment with 2 doses of fulvestrant (250 vs 500 mg) in postmenopausal women with locally advanced or metastatic estrogen receptor (ER)-positive breast cancer that had recurred or progressed after endocrine therapy. The primary analysis showed that progression-free survival was significantly increased with fulvestrant 500 versus 250 mg [Di Leo A et al. J Clin Oncol 2010]. This article discusses the final analysis of overall survival.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
